Bolt Biotherapeutics, Inc.: Diferență între versiuni

Bolt Biotherapeutics, Inc (www.boltbio.com) is a clinical-stage immuno-oncology company. The Company is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Its Immune-Stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells, including macrophages and dendritic cells, that kill tumor cells via phagocytosis and expose tumor neoantigens to the adaptive immune system. The Company’s product candidate BDC-1001 is a human epidermal growth factor receptor 2 (HER2) Boltbody ISAC comprised of a HER2-targeting biosimilar, of trastuzumab conjugated to one of its TLR7/8 agonists, for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. Its Toll-like receptors (TLRs) activate myeloid cells and enable the presentation of tumor-associated neoantigens to cytotoxic T cells.